QDEL logo

QDEL

QuidelOrtho CorporationNASDAQHealthcare
$17.25+4.04%ClosedMarket Cap: $1.17B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

PEG

P/B

0.56

P/S

0.40

EV/EBITDA

-7.59

DCF Value

$-44.30

FCF Yield

2.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

46.7%

Operating Margin

-33.7%

Net Margin

-41.5%

ROE

-46.4%

ROA

-19.6%

ROIC

-18.5%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$723.6M$-130.7M$-1.95
FY 2025$2.73B$-1.13B$-16.69
Q3 2025$699.9M$-733.0M$-10.78
Q2 2025$613.9M$-255.4M$-3.77

Analyst Ratings

View All
CitigroupNeutral
2026-02-12
UBSNeutral
2026-01-21
JP MorganUnderweight
2025-11-07
UBSNeutral
2025-11-06
CitigroupNeutral
2025-10-07

Trading Activity

Insider Trades

View All
SISITSKY NATHANIELofficer: Chief Legal Officer
SellTue Mar 31
Busky Joseph M.officer: Chief Financial Officer
SellTue Mar 31
Busky Joseph M.officer: Chief Financial Officer
SellTue Mar 31
Busky Joseph M.officer: Chief Financial Officer
SellTue Mar 31
Hanson Bryan Michaelofficer: EVP Global Port. Mgmt & Mkting
SellTue Mar 24

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NASDAQ

Beta

0.92

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Peers